In addition, two other meta-analyses consistently demonstrated that high SOX2-OT expression is significantly associated with worse overall survival, advanced clinical stage, worse tumor differentiation, earlier distant metastasis, and earlier lymph node metastasis in various cancers [39, 41, 46]. The gene discussed is SOX2; the disease is neoplasm.